In a real-world cohort of 44,415 adults with type 2 diabetes and CKD (8,783 receiving combination therapy and 35,532 receiving SGLT-2 inhibitor monotherapy), combination treatment with GLP-1 receptor agonists and SGLT-2 inhibitors resulted in significantly smaller declines in kidney function (93). Here, SLC5A2 is linked to type 2 diabetes mellitus.